Form 4 for ACRV Acrivon Therapeutics, Inc.
Accepted 2023-06-01 00:00:00 ET · period of report 2023-05-31 · accession 0001140361-23-027860 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-06-01 | 2023-05-31 | ACRV | Blume-Jensen Peter | Pres, CEO, Dir | M - OptEx | $3.88 | +33.6K | 2.40M | +1% | +$130.4K |
| D | 2023-06-01 | 2023-05-31 | ACRV | Blume-Jensen Peter | Pres, CEO, Dir | M - OptEx | $0.00 | -33.6K | 90.9K | -27% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-31 | M | A | 33,605 | $3.88 | 2,403,702 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-05-31 | M | D | 33,605 | $0.00 | 90,855 | D | $3.88 · — to 2032-03-22 | 33,605 Common Stock | (F2) The shares subject to the option vested or shall vest quarterly on the last day of each quarter for 16 quarters following January 1, 2022, in each case subject to the Reporting Person's continuous service through each such vesting date. (F3) The expiration date for these options was inadvertently reported as April 5, 2032 on the Form 3 filed by the Reporting Person on November 9, 2022, and has been corrected as of this Form 4. |